Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
Study sponsor: Mineralys Therapeutics Inc. · MLYS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-12-10Actual
Enrollment · participants1083Actual
Source updated2026-05-01Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.